VIP in plain English — the multi-organ vasoactive peptide

Somewhere in that moment, a 28-amino-acid peptide is doing its job — or failing to. The peptide is called Vasoactive Intestinal Peptide. You almost certainly have never heard of it. That asymmetry, between how much it does in the body and how rarely it comes up in clinical conversation, is the thing worth understanding.

VIP was discovered in 1970 by two researchers: Sami Said, a pulmonologist working in New York, and Viktor Mutt, a Swedish biochemist. They were not looking for a systemic regulator. Said was studying gut tissue — specifically, what happened to blood vessels in the small intestine — and he found a peptide that, when extracted from porcine duodenum and injected, caused immediate vasodilation. The name came from that first observation. Vasoactive. Intestinal. Peptide. The full scope of what it would turn out to do was not on anyone's radar in 1970.

It took decades of subsequent research to reveal the picture. VIP is not a gut peptide that incidentally turns up elsewhere. It is a neuropeptide — synthesized by neurons — that is expressed throughout the body in concentrations that shift depending on what the tissue needs. It is found in the enteric nervous system that governs gut motility. It is found in lung tissue, where it governs bronchial smooth muscle tone. It is found in the pancreas, where it modulates insulin and glucagon secretion. It is found in the central nervous system, including the hypothalamus, where it plays a role in circadian rhythm. It is found in immune tissue — lymph nodes, thymus, the cells of the immune system itself. No single organ owns VIP. It is, more accurately, a language that several different organ systems speak.

The mechanism depends on where you are in the body, but the core signal is consistent. VIP binds to two main receptor types: VPAC1 and VPAC2. These are G-protein-coupled receptors, meaning they sit in the cell membrane and transmit signals inward by coupling to proteins inside the cell. When VIP binds, these receptors activate adenylyl cyclase, which converts ATP to cyclic AMP — cAMP. Cyclic AMP is a second messenger, a molecular relay, and what it does next depends on the cell type receiving the signal. In smooth muscle cells, elevated cAMP leads to relaxation. In immune cells, elevated cAMP leads to a shift in cytokine output — less TNF-α, less IL-6, more of the anti-inflammatory signals like IL-10. In the hypothalamic suprachiasmatic nucleus — the brain's master clock — VIP-producing neurons coordinate the firing of individual clock cells into a synchronized circadian signal.

The same peptide. Very different downstream effects. This is not confusion in the biology. It is a design feature.

The bronchodilation story is among the most studied. The airways are lined with smooth muscle, and that smooth muscle is under constant competing signals — constricting signals from acetylcholine and histamine, dilating signals from the autonomic nervous system and, critically, from VIP. VIP is co-stored with the neurotransmitter acetylcholine in nerve endings that innervate the lung. When airway smooth muscle needs to relax — during exhalation, during recovery from a constricting stimulus — VIP is part of the signal. Research going back to the 1980s showed that people with severe asthma had lower concentrations of VIP-containing nerve fibers in their airways than controls. Whether this is cause or consequence remains a genuine question in the literature. But the observation has held up: a lung with impaired VIP signaling has a harder time relaxing than it should.

Gut motility is the other classical domain. The enteric nervous system — sometimes called the second brain — contains more neurons than the spinal cord, and those neurons produce VIP in quantity. In the gut, VIP coordinates peristalsis: the rhythmic contractions that move food through the intestine. It relaxes the sphincters that separate compartments. It regulates secretion into the gut lumen. When VIP-producing neurons are damaged — as happens in the rare condition Hirschsprung's disease, or in certain autoimmune processes that attack enteric neurons — the gut loses its rhythmicity. The clinical picture is constipation, bloating, pain, and the particular misery of a gut that doesn't know where to go next. VIPomas — tumors that produce VIP in excess — cause the opposite problem: massive secretory diarrhea. The range from deficiency to excess maps onto a range of clinical phenomena that most gastroenterologists manage without ever naming VIP as the mechanism.

The immune angle is where recent therapeutic interest has concentrated most sharply, and it requires understanding what VIP is doing in immune tissue. VPAC1 receptors are expressed on T cells, B cells, macrophages, and dendritic cells. VPAC2 receptors are expressed on mast cells and natural killer cells. When VIP activates these receptors, the downstream effect is reliably anti-inflammatory in character: it suppresses the production of pro-inflammatory cytokines, promotes the differentiation of regulatory T cells, and reduces the activation of macrophages in ways that shift the immune response away from inflammatory attack and toward resolution. This is not immunosuppression in the crude sense — it doesn't knock out immune function the way steroids do. It is more like a tuning signal, shifting the immune system's balance toward tolerance and resolution rather than continued reactivity.

That distinction matters enormously in conditions where the problem is not insufficient immune response but dysregulated immune response — where the immune system is fighting the wrong things, or continuing to fight after the initial trigger has resolved.

The research on VIP in pulmonary arterial hypertension is among the most developed in a serious clinical context. Pulmonary hypertension involves pathological remodeling of the pulmonary vasculature — the blood vessels narrow, pressure rises, and the right heart strains against the resistance. VIP's vasodilatory effects in pulmonary vasculature are well-established in preclinical models, and early clinical research explored inhaled VIP as a delivery mechanism. The results were promising enough to generate real interest but limited enough to make clear that translation from mechanism to therapeutic is not straightforward. Inhaled VIP has a short half-life — measured in minutes — and delivering enough of it to sustain vasodilation long enough to matter clinically requires solving stability and delivery problems that have not been fully solved.

The sarcoidosis research is earlier stage. Sarcoidosis is a granulomatous disease — the immune system forms clusters of inflammatory cells, called granulomas, in various organs, often the lungs and lymph nodes. The immunological picture involves dysregulated macrophage activation, elevated TNF-α, and a failure of normal immune resolution. VIP's anti-inflammatory and immunomodulatory properties have made it a candidate for investigation in this context, particularly as researchers look for approaches that could address the underlying immune dysregulation rather than just suppressing it broadly with corticosteroids. The research here is preclinical and early. The hypothesis is biological sound. The clinical evidence is thin.

Mast cell disorders represent another domain where VIP has attracted serious attention, primarily because of the VPAC2 receptor expression on mast cells. Mast cells are innate immune cells that release a cascade of inflammatory mediators — histamine, tryptase, prostaglandins, and dozens of others — when activated. When mast cells are hyperactivated, as in Mast Cell Activation Syndrome, this cascade fires inappropriately. VIP, via VPAC2, appears to modulate mast cell activity in ways that reduce inappropriate activation, a mechanism that has supported both investigational research and clinical interest among providers who work with MCAS patients. This is investigational territory. The evidence base for VIP specifically in MCAS involves case series and clinical observation rather than randomized controlled trials.

Long COVID has brought VIP into a different conversation entirely. Researchers studying the immune dysregulation underlying prolonged post-COVID symptoms have noted patterns — elevated inflammatory cytokines, disrupted autonomic regulation, mast cell involvement — that intersect with what VIP physiology would predict matters. Several research groups have investigated VIP levels in acute COVID and in long COVID populations, and low circulating VIP has appeared as a feature in some cohorts, though the sample sizes are small and the causal relationships are not established. The hypothesis that restoring VIP signaling might help address some component of the immune and autonomic dysregulation in long COVID is mechanistically coherent. What it is not, yet, is evidence.

The honest summary of where VIP sits therapeutically is this: the biology is genuinely remarkable, the mechanisms are well-characterized at the molecular level, and the translational research is moving in several directions at once. Inhaled VIP, intranasal VIP, and subcutaneous VIP have all been explored in different contexts. None of these approaches has generated the kind of large randomized controlled trial data that would support an approved therapeutic indication for the immune and inflammatory conditions where interest is highest. What exists is a constellation of mechanistic research, early-phase clinical observations, and clinical practice by providers who have evaluated individual patients and concluded, based on the available data, that the risk-benefit calculus supports a trial in certain cases.

VIP is not a simple drug targeting a single problem. It is a regulatory molecule that the body uses to maintain balance across many different systems simultaneously, and understanding it as such requires holding the breadth and the limitations together. The peptide that Said and Mutt found in porcine gut tissue fifty-some years ago has turned out to be something considerably more interesting than its name implies. The full picture is still being drawn.